<DOC>
	<DOC>NCT02855359</DOC>
	<brief_summary>This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.</brief_summary>
	<brief_title>Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma</brief_title>
	<detailed_description>In Part A of the study, patients will be randomized 1:1 to receive denintuzumab mafodotin plus RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or denintuzumab mafodotin plus RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) to assess the safety of these 2 combination regimens. Part B of the study is designed to evaluate the antitumor activity and safety of denintuzumab mafodotin in combination with either RCHOP or RCHP (Experimental Arm) compared with RCHOP alone (Comparator Arm).</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Treatmentnaive patients with histologically confirmed systemic de novo or transformed diffuse large Bcell lymphoma (DLBCL) (from follicular or marginal zone lymphoma), or follicular lymphoma (FL) Grade 3b; patients must have high intermediate or high risk disease Tumor tissue available from most recent biopsy to determine cell of origin Fluorodeoxyglucoseavid disease by positron emission tomography and measurable disease greater than 1.5cm diameter Eastern Cooperative Oncology Group performance status â‰¤2 Age 18 years or older Adequate study baseline laboratory parameters Previous history of treated indolent lymphoma History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years History of progressive multifocal leukoencephalopathy Cerebral/meningeal disease related to the underlying malignancy Patients with the following ocular conditions: corneal disorders, monocular vision (ie. best corrected visual acuity greater than or equal to 20/200 in one eye), or active ocular disorders requiring treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>SGN-19A</keyword>
	<keyword>Denintuzumab Mafodotin</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD19</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma, B-Cell</keyword>
	<keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Monomethyl auristatin F</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms by Histologic Type</keyword>
	<keyword>Transformed Lymphoma / DLBCL</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Liposomal doxorubicin</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Alkylating Agents</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Antibiotic, Antineoplastic</keyword>
	<keyword>Antimitotic Agents</keyword>
	<keyword>Antineoplastic Agents, Alkylating</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Phytogenic Antirheumatic Agents</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Follicular Lymphoma Grade 3b</keyword>
	<keyword>immunosuppressive agents</keyword>
</DOC>